Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.54 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1795022 | 0.89 | MEN1 (0.75) | MEN1KMT2ANR4A2GLRA1MAOB | |
| SCHEMBL26574732 | 0.89 | MEN1 (0.70) | MEN1KMT2ANR4A2GLRA1MAOB | |
| SCHEMBL10200052 | 0.88 | MEN1 (0.79) | MEN1KMT2ATSHRSMN1; SMN2NR4A2 | |
| SCHEMBL28515116 | 0.85 | MEN1 (0.60) | MEN1KMT2ASMN1; SMN2NR4A2GLRA1 | |
| SCHEMBL16137683 | 0.84 | MEN1 (0.62) | MEN1KMT2ANR4A2GLRA1MAOB | |
| SCHEMBL3132629 | 0.83 | LMNA (0.62) | MEN1KMT2ATSHRSMN1; SMN2NR4A2 | |
| SCHEMBL339690 | 0.82 | MEN1 (0.65) | MEN1KMT2ASMN1; SMN2NR4A2GLRA1 | |
| SCHEMBL16115550 | 0.82 | KMT2A (0.60) | MEN1KMT2ANR4A2GLRA1MAOB | |
| SCHEMBL4910012 | 0.82 | MEN1 (0.62) | MEN1KMT2ATSHRSMN1; SMN2NR4A2 | |
| SCHEMBL3271153 | 0.82 | CYP4F2 (0.61) | MEN1KMT2ATSHRSMN1; SMN2NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | MEN1 2493/4885KMT2A 2015/4885TSHR 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.